What is CAR-T cell therapy?

CAR-T cell therapy is a type of immunotherapy that uses a patient's own immune system in addition to gene engineering technology.

T cells, a type of immune cells, are collected from a patient's blood, and the T cells are genetically modified to produce artificial receptors on their surface called “chimeric antigen receptors (CARs)”. CARs are receptor proteins that allow the T cells to recognize a surface antigen on cancer cells. CAR-T cells are then grown until they number in the billions and infused to the patient after 10 days to two weeks of being cultured in a laboratory.


After the infusion, the T cells multiply in the patients’ body, and genetically enginieered CAR-T cells recognize surface protein antigens on cancer cells and begin to attack it as a target. 

Strategic business plan with next generation CAR-T platform against solid cancers

1.  Augmentation of gene-engineered T cell function for appropriate expansion, accumulation, and inducible memory function to solid cancer

  • Enhanced accumulation and persistence of T cells in the tumor sites.
  • Significant antitumor benefits have been confirmed in vitro and in vivo
  • Safety switch with suicide gene system. 
  • Exclusive license from Yamaguchi University (WO/2016/056228). 

2.  Business alliance in the development of novel T cell therapy platform for solid tumors

3.  Exploring novel target antigen for CAR-T therapy

  • Next generation CAR-T platform can be used for various CAR-T development against distinct solid tumors

4.  Process development to secure a stable supply of CAR-T

  • Automated cell culture system for securing stable and cost-effective supply

Prime (Proliferation-inducing and Migration-enhancing) CAR-T technology